Original Research
Evaluation of adverse effects of AstraZeneca COVID-19 vaccine after the first dose in Libyan adults: a cross-sectional study
Fatima E. Alhaddad and Khaleel M. Abuleid
Abstract :
In January 2021, cases affected by the coronavirus epidemic are constantly increasing, the Libyan Ministry of Health provides the vaccine to the people who are most at risk. The purpose of this study was to assess and verify the adverse effects of the first dose of the AstraZeneca COVID-19 vaccine. The study was conducted at the Aljmail city, west region of Libya. The study was cross-sectional study during the period of August 31st and November 5th, 2021. The method involved 133 adult Libyan participants of both genders aged more than 18 years old. The preliminary data were 54.0% who developed post-vaccination symptoms. The participants aged 60 years and older with chronic diseases were more likely to have adverse effects after receiving the first dose of the vaccine. In conclusion, the AstraZeneca vaccine was good and effective but this study indicates a need for a large and long period study to confirm the safety of the vaccine use in adult people.
References
1. European Medicines Agency (2021, November 25) EMA recommends COVID-19 vaccine AstraZeneca for authorization in the EU. EMA. Science Medicine Health. January 29, 2021.
2. Mohamadian M, Chiti H, Shoghli A, Biglari S, Parsamanesh N, Esmaeilzadeh A (2021) Covid‐19: Virology, biology and novel laboratory diagnosis. The Journal of Gene Medicine. 23 (2): e3303. doi: 10.1002/jgm.3303
3. Fuchs VR (2020) Health care policy after the COVID-19 pandemic. JAMA. 324 (3): 233-234. doi: 10.1001 /jama.2020.10777
4. Tobaiqy M, Elkout H, MacLure K (2021) Analysis of thrombotic adverse reactions of COVID-19 AstraZeneca vaccine reported to EudraVigilance database. Vaccines. 9 (4): 393. doi: 10.3390/vaccines9040393.
5. Alghamdi A, Ibrahim A, Almutairi R, Joseph M, Alghamdi G, Alhamza A (2021) A cross-sectional survey of side effects after covid-19 vaccination in Saudi Arabia: male versus female outcomes. Journal of Advanced Pharmacy Education and Research. 11(2): 51-56. doi: 10.51847/bcwca2qgfp
6. Almufty HB, Mohammed SA, Abdullah AM, Merza MA (2021) Potential adverse effects of COVID-19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes & Metabolic Syndrome. 15 (5): 102207. doi: 10.1016/j.dsx.2021.102207
7. Xiong X, Yuan J, Li M, Jiang B, Lu ZK (2021) Age and gender disparities in adverse events following covid-19 vaccination: Real-world evidence based on big data for risk management. Frontiers in Medicine. 8: 700014. doi: 10.3389/fmed.2021.700014
8. Alemayehu A, Demissie A, Yusuf M, Abdullahi Y, Abdulwehab R, Oljira L, Feleke D (2022) COVID-19 vaccine side effect: age and gender disparity in adverse effects following the first dose of AstraZeneca covid-19 vaccine among the vaccinated population in eastern Ethiopia: a community-based study. SAGE Open Medicine. 10, 205031212211086. doi: 10.1177/20503121221108616
9. Sultana A, Shahriar S, Tahsin MR, Mim SR (2021) A retrospective cross-sectional study assessing self-reported adverse events following immunization (AEFI) of the COVID-19 vaccine in Bangladesh. Vaccines. 9 (10): 1090. doi: 10.3390/vaccines9101090
10. Riad A, Sağıroğlu D, Üstün B, Pokorná A, Klugarová J, Attia S, Klugar M (2020) Prevalence and risk factors of CORONAVAC side effects: An independent cross-sectional study among healthcare workers in Turkey. Journal of Clinical Medicine. 10 (12): 2629. doi: 10.3390/jcm10122629
Citation :
Alhaddad FE, Abuleid KM (2022) Evaluation of adverse effects of AstraZeneca COVID-19 vaccine after the first dose in Libyan adults: a cross-sectional study. Mediterr J Pharm Pharm Sci. 2 (4): 65-69. [Article number: 91]. https://doi.org/10.5281/zenodo.7479778